Pre-solicitationPosted Jun 30, 2026·Responses due Jun 21, 2023

M5-Q50A-03-R8: 65IB Drugs, Pharmaceuticals & Hematology Related Products Solicitation Refreshment

Veterans Affairs · NAC FEDERAL SUPPLY SCHEDULE (36F797)

Stage
Early notice (sources sought, presolicitation or special notice)
NAICS
325412
Value
Not stated
Solicitation
M5Q50A03R8
Set-aside
None stated
PSC
6505
Place
Not stated
Contact
FSS Help Desk (FSS.help@va.gov)
Loading your pipeline and notes…
CSV Email

Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.

Where this opportunity stands

Every notice posted under solicitation M5Q50A03R8 in this department, oldest first.

Early notice
  • Jun 30, 2026 · this notice
    Pre-solicitation
  • Oct 13, 2026
    Special Notice
    Open
Solicitation
None posted
Award
  • Oct 12, 2023
    Award Notice
    PROVENTION BIO INC · $5.0M
    Open
  • Nov 6, 2023
    Award Notice
    SCPHARMACEUTICALS INC. · $601K
    Open
  • Apr 11, 2024
    Award Notice
    Bristol-Myers Squibb Company · $12.3B
    Open
  • May 22, 2024
    Award Notice
    ZANFEL LABORATORIES, INC
    Open
  • Jun 26, 2024
    Award Notice
    PHATHOM PHARMACEUTICALS, INC. · $250K
    Open
  • Sep 12, 2024
    Award Notice
    FIRST NATION GROUP LLC
    Open
  • Dec 6, 2024
    Award Notice
    DAY ONE BIOPHARMACEUTICALS, INC
    Open
  • May 12, 2025
    Award Notice
    NATIONAL VITAMIN CO., INC
    Open
  • Jul 11, 2025
    Award Notice
    BRIDGEBIO PHARMA, INC. · $250K
    Open
  • Jul 28, 2025
    Award Notice
    SOLENO THERAPEUTICS INC
    Open
  • Aug 13, 2025
    Award Notice
    IONIS PHARMACEUTICALS, INC.
    Open
  • Feb 13, 2026
    Award Notice
    MESOBLAST, INC.
    Open
  • Apr 27, 2026
    Award Notice
    MESOBLAST, INC.
    Open
  • May 27, 2026
    Award Notice
    NEUROCRINE BIOSCIENCES, INC.
    Open
  • Aug 27, 2026
    Award Notice
    RECKITT BENCKISER LLC
    Open
  • Sep 25, 2026
    Award Notice
    WILSHIRE PHARMACEUTICALS, INC · $27.2M
    Open

Next steps for this stage

Standard steps for the notice type; not advice about this buyer.

  • Answer the notice: this is when the requirement can still be shaped.
  • Contact the contracting officer named on the notice.
  • Check who won similar work; they are the likely bidders.

What the notice says

M5-Q50A-03-R8: 65IB Drugs, Pharmaceuticals & Hematology Related Products Solicitation Refreshment

Who won similar work

76 award notices on SAM.gov in the last 24 months. Matched by: Same office (NAC FEDERAL SUPPLY SCHEDULE (36F797)), same product/service code (PSC) 6505 and NAICS 325412.

Single-winner award sizes (74): middle half $721K to $173.8M, median $24.4M; range $225K to $8.0B.

WinnerAwardsValueLast
VALNEVA USA, INC.2$4.3MSep 29, 2025
ELI LILLY AND COMPANY · $LLY · $34.1B1$8.0BSep 17, 2025
MERCK SHARP & DOHME LLC · $MRK · $60.1B1$5.8BMay 22, 2025
Takeda Pharmaceuticals America, Inc.1$5.6BAug 7, 2026
BAUSCH HEALTH US LLC · $BHC · $8.8B1$3.7BSep 14, 2026
SUMITOMO PHARMA AMERICA, INC.1$2.9BAug 24, 2026
ALKERMES, INC. · $ALKS · $1.7B1$1.7BJul 10, 2026
UCB, INC1$1.1BSep 9, 2025
IPSEN BIOPHARMACEUTICALS INC1$760.7MMay 28, 2026
Indivior Inc.1$748.9MApr 27, 2026

Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.

Investor context
  • $LLY reported $34.1B revenue in FY2025. The median single-winner award in these 74 past awards, $24.4M, is under 0.1% of that. 10-K
  • $MRK reported $60.1B revenue in FY2025. The median single-winner award in these 74 past awards, $24.4M, is under 0.1% of that. 10-K
  • $BHC reported $8.8B revenue in FY2025. The median single-winner award in these 74 past awards, $24.4M, is 0.3% of that. 10-K
  • $ALKS reported $1.7B revenue in FY2025. The median single-winner award in these 74 past awards, $24.4M, is 1% of that. 10-K

One award's total value against one year of revenue; many awards are paid over several years.

Latest awards

Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.

Competitive landscape

For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.

  • 1 of these past winners lobbied Veterans Affairs, Dept of (VA) since 2024 (14 filings)
  • 0 of their lobbyists list a past Veterans Affairs, Dept of (VA) job
  • $140K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Veterans' Affairs, Senate Committee on Appropriations, Senate Committee on Veterans' Affairs
  • 0 foreign-agent (FARA) registrations
See who and the source records with Pro

Policy around it

Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.

  • 8 bills named on the past winners' lobbying filings
  • 25 rules from the department in the last 12 months
  • 0 executive orders naming the agency in the last 12 months
See who and the source records with Pro

Market

For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.

  • 4 of the past winners are listed companies
  • 0 insider buys and 17 insider sells at them in the last 90 days
See who and the source records with Pro

Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.

Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.